TriSalus Q1 revenue $8.9M (-2.9% YoY); revises FY 2026 guidance to $54-57M

TriSalus Life Sciences, Inc.

2026-Q1 EPS reported $0.03 revenue$8,899,000

Revenue $8.9M, down 2.9% YoY; gross margin improved to 86.2% from 83.7%.
Net income $1.5M ($0.03 EPS) on $11.3M non-cash derivative gains; adj. EBITDA loss $5.8M.
Raised $46M in equity; cash $56.6M to fund commercial expansion and pipeline.
2026 revenue guidance revised to $54-57M, reflecting commercial expansion and TriNav Advance FDA clearance delay.
Appointed Richard Marshall as Chief Medical Officer effective June 29, 2026; added board member Michael Stansky.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

TriSalus Life Sciences, Inc. reported the quarter ended March 31, 2026 results: revenue $8.9 million, net income $1.5 million, EPS $0.03.

Period: the quarter ended March 31, 2026
Revenue: $8.9 million
Net income: $1.5 million
EPS: $0.03
Result: reported results

Exact text from the filing

Revenue from the sale of the TriNav system, was $8.9 million for the three months ended March 31, 2026, a decrease of 2.9% compared to the same period in 2025.

View on SEC.gov

Browse all earnings releases →

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-034082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.